PDE

An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond

23 views | Jan 30 2024

Advances in IPF research are driving an exponential surge in clinical trials testing novel treatments, aiming not only to stabilize but potentially reverse the fibrotic process, signaling a promising shift toward expanded therapeutic options and improved patient outcomes. [Read the Full Post]

The relationship between discrimination, alcohol use severity, and PTSD symptoms among Latinx heavy drinkers

32 views | Jan 27 2024

This study underscores how discrimination's impact on alcohol use severity among Latinx adults is intricately connected to PTSD symptoms, highlighting the need for culturally adapted interventions tailored to those with higher PTSD symptomatology. [Read the Full Post]

Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis

31 views | Jan 02 2024

Baseline serum MIF levels in primary progressive MS correlated with faster brain atrophy, showing a sex disparity with higher levels in males, while ibudilast treatment didn't significantly alter MIF levels. [Read the Full Post]

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials

33 views | Sep 07 2023

The phase 3 clinical trials of ziritaxestat, an autotaxin inhibitor, showed no improvement in clinical outcomes compared to placebo in patients with idiopathic pulmonary fibrosis (IPF), regardless of whether they were receiving standard of care treatment or not. [Read the Full Post]

[18F]ONO-8430506: A novel radioligand for PET imaging of autotaxin (ATX)

11 views | Sep 07 2023

The novel radioligand [18F]ONO-8430506 ([18F]8) showed promising inhibitory potency against ATX but exhibited relatively low tumor uptake and retention in PET imaging studies. [Read the Full Post]

Inhibition of Autotaxin Ameliorates LPA-Mediated Neuroinflammation and Alleviates Neurological Dysfunction in Acute Hepatic Encephalopathy

28 views | Jul 23 2023

The study demonstrated that treatment with an autotaxin inhibitor attenuated neuroinflammation, reduced levels of LPA and inflammatory markers, improved neurobehavioral symptoms, and ameliorated brain edema in a mouse model of hepatic encephalopathy. [Read the Full Post]

Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells

33 views | Mar 29 2023

The study identifies novel druggable targets and potential combined drug, immunotherapy, and RNA vaccine approaches for treating glioblastoma, but effective pan-GBM drug treatment remains challenging due to extreme heterogeneity within drug-treated cells. [Read the Full Post]

Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer

21 views | Mar 29 2023

PDE10A may be a promising target for ovarian cancer chemoprevention and treatment, as its inhibition leads to decreased ovarian cancer cell growth and induces cell cycle arrest and apoptosis through PKA and PKG signaling and decreased activation of oncogenic and inflammatory signaling pathways. [Read the Full Post]

Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium

31 views | Feb 20 2023

Levosimendan increased force of contraction in the mouse left atrial preparations in the presence of rolipram and had positive inotropic and chronotropic effects in both mouse and human atrial preparations, with the positive inotropic effect being explained by phosphodiesterase III inhibition leading to phospholamban phosphorylation in the human atrium. [Read the Full Post]

Therapeutic treatment with phosphodiesterase-4 inhibitors alleviates kidney injury and renal fibrosis by increasing MMP-9 in a doxorubicin-induced nephrotoxicity mouse model

33 views | Feb 20 2023

PDE-4 inhibitors rolipram and roflumilast showed beneficial effects in preserving glomerular filtration barrier function, reducing inflammation, and decreasing renal fibrosis in a doxorubicin-induced nephrotic syndrome model, with roflumilast having better effects in reducing glomerular and tubular lesions and MMP9 activity in renal tissue at later stages. [Read the Full Post]